P255 Proactive therapeutic drug monitoring and dose escalation are associated with sustained intravenous infliximab persistence beyond five years
James Hassall, Thean Chew, MF Hale, Anupam Rej et autres
Introduction Infliximab (IFX) improves outcomes in Inflammatory Bowel Disease; however secondary loss of response (LOR) occurs in up to 60% of patients at 3 years. Data on long–term outcomes following proactive therapeutic drug monitoring (TDM) combined with IFX dose escalation (DE) is …
gb (code pays fourni par la source)